Preliminary clinical evaluation of a protein chip for tumor marker serodiagnosis of various cancers

Asian Pacific Journal of Allergy and Immunology

Volumn 21, Issue 3, 2003, Pages 171-178

  Balachandra, Kruavon ^a   Laisupasin, Pikul ^a   Dhepakson, Panadda ^a   Warachit, Jiranan ^a   Jantraraksri, Udom ^a   Issaragrisil, Surapol ^b   Yang, Xiang Li ^c   Hu, Geng Xi ^c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BREAST CANCER; CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SCREENING; CLINICAL STUDY; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; METASTASIS; OVARY CANCER; PANCREAS CANCER; PERIODIC MEDICAL EXAMINATION; PROSTATE CANCER; PROTEIN MICROARRAY; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; STOMACH CANCER; THAILAND; UTERINE CERVIX CANCER;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN ARRAY ANALYSIS; SEROLOGIC TESTS; THAILAND; TUMOR MARKERS, BIOLOGICAL;

EID: 1542375432     PISSN: 0125877X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. American Cancer Society: Cancer Facts and Figures-2002. Atlanta, Ga: American Cancer Society, 2002.
2. Moss SM. Case-control studies of screening. Int J of Epidemiol 1991; 20: 1-6.
3. Weiss NS, Lazovich D. Case-control studies of screening efficacy: the use of persons newly diagnosed with cancer who later sustain an unfavorable outcome. Am J Epidemiol 1996; 143: 319-22.
4. Black WC, Haggstrom DA, Welch HG. All-cause mortality in randomized trials of cancer screening. Natl Cancer Inst 2002; 94: 167-73.
5. Smith RA, Cokkinides V, Von Eschenbach AC, Levin B, Cohen C, Runowiez CD, Sener S, Sasloe D, Eyre HJ. American Cancer Society Guidelines for the Early Detection of Cancer. CA Cancer J Clin. 2002; 52: 8-22. AC, Levin B, Cohen C, Runowiez CD, Sener S, Sasloe D, Eyre HJ. American Cancer Society Guidelines for the Early Detection of Cancer. CA Cancer J Clin. 2002; 52: 8-22.
6. Goldstein NS, Blue DE, Hankin R, Hunter S, Bayati N, Silverman AL and Gordon SC. Serum alpha-fetoprotein levels in patients with chronic hepatitis C. Relationships with serum alanine aminotransferase values, histologic activity index, and hepatocyte MIB-1 scores. Am J Clin Pathol. 1999; 111: 811-6.
7. Vessella RL, Lange PH. Issues in the assessment of PSA immunoassays. Urol Clin North Am 1993; 20: 607-19.
8. Lilja H, Haese A, Bjork T, Friedrich MG, Piironen T, Pettersson K, Huland E and Huland H. Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy. J Urol 1999; 162: 2029-4.
9. Arafah BM, Nasrallah MP. Pituitary tumors: pathophysiology, clinical manifestations and management. Endocr Relat Cancer 2001; 8: 287-305.
10. Cauchi MN, Koh SH, Lim D, Hay DL. Oncofoetal antigens in cancer of the cervix and ovary. Br J Cancer 1981; 44: 403-9.
11. Higashida T, Koizumi T, Yamaguchi S, Ichimura T, Hasegawa K, Nishimura R. Ovarian malignant mixed mesodermal tumor producing the free form of the beta-subunit of human chorionic gonadotropin. Int J Clin Oncol 2001; 6: 97-100.
12. Kinugasa M, Nishimura R, Hasegawa K, Okamura M, Kimura A, Ohtsu F and Takeuchi K. Assessment of urinary beta-core fragment of hCG as a tumor marker of cervical cancer. Nippon Sanka Fujinka Gakkai Zasshi 1992; 44: 188-94.
13. Ferdeghini M, Gadducci A, Prontera C, Castellani C, Annicchiarico C, Gagetti O, Facchin V and Bianchi R. Determination of serum levels of different cytokeratins in patients with uterine malignancies. Anticancer Res 1994; 14: 1393-7.
14. Meden, H. and Fattahi-Meibodi A. CA 125 in benign gynecological conditions. Int J Biol Markers 1998; 13: 231-7.
15. Berruti A, Tampellini M, Torta M, Buniva T, Gorzegno G, Dogliotti L. Prognostic value in predicting overall survival of two mucinous markers: CA15-3 and CA125 in breast cancer patients at first relapse of disease. Eur J Cancer 1994; 30A: 2082-4.
16. Colomer R, Ruibal A, Genolla J, Rubio D, Del Campo JM, Bodi R, Salvador L. Circulating CA15-3 levels in the post-surgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res Treat 1989; 13: 123-33.
17. Podczaski E, Kaminski P, Hackett TE, Olt GJ, Zaino R. Tissue CA125 and CA19-9 in malignant, mixed mesodermal tumors of the uterus. Gynecol Oncol 1993; 49: 56-60.
18. Torok, N, Gores GJ. Cholangiocarcinoma. Semin Gastrointest Dis 2001; 12: 125-32.
19. Torzilli G, Makuuchi M, Ferrero A, Takayama T, Hui AM, Abe H, Inoue K, Nakahara K. Accuracy of the preoperative determination of tumor markers in the differentiation of liver mass lesions in surgical patients. Hepatogastroenterology. 2002; 49: 740-5.
20. Hasholzner U, Stieber P, Reiter W, Zimmermann A, Hofmann K, Schalhorn A. CA242 in comparison with established tumour markers in colo-rectal, pancreatic and lung cancer Anticancer Res 1999; 19(4A): 2477-80
21. Bolarin DM. Serum ferritin in Nigerian patients with Burkitt's lymphoma and other malignant diseases. Acta Trop 1983; 40: 71-7.
22. Song JS, Park W, Bae SK, Kim SS, Lee YH, Choi JW, Kim SK. The usefulness of serum transferrin receptor and ferritin for assessing anemia in rheumatoid arthritis: comparison with bone marrow iron study. Rheumatol Int 2001; 21: 24-9.
23. Ebert W, Muley T, Trainer C, Dienemann H and Drings P. Comparison of changes in the NSE levels with clinical assessment in the therapy monitoring of patients with SCLC. Anticancer Res 2002; 22: 1083-9.
24. Satoh H, Ishikawa H, Kurishima K, Yamashita YT, Ohtsuka M, Sekizawa K. Cut-off levels of NSE to differentiate SCLC from NSCLC. Oncol Rep 2002; 9: 581-3.
25. Ebeling FC, Schmitt UM, Untch M, Nagel D, Fateh-Moghadam A, Stieber Pand Seidel D. Tumour markers CEA and CA15-3 as prognostic factors in breast cancer-univariate and multivariate analysis. Anticancer Res 1999; 19: 2545-50.
26. Juang CM, Wang PH, Yen MS, Lai CR, Ng HT, Yuan CC. Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix. Gynecol Oncol 2000; 76: 103-6.
27. Maussier ML, Valenza V, Schinco G, Galli G. AFP, CEA, CA19-9 and TPA in hepatocellular carcinoma. Int J Biol Markers 1990; 5: 121-6.
28. Black WC. Overdiagnosis: an under-recognized cause of confusion and harm in cancer screening. Natl Cancer Inst 2000; 92: 1280-2.
29. McIntosh MW, Urban N, Karlan B. Generating Longitudinal Screening algorithms using novel biomarkers for disease. Cancer Epidemiol Biomarkers Prev 2002; 11: 59-66.
30. Fujuyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, Tomita K. Tumor marker in early diagnosis follow-up and management of patients with hepatocellular carcinoma. Oncology 2002; 62 (suppl): 57-63.
31. Guadagni F, Ferroni P, Carlini S, Mariotti S, Spila A, Aloe S. D'Alessan dro, Caribe DM, Cicchetti A, Ricciott A,Venturo I, Pasquale P, Filippo DF, Cognetti F, Botti C, Poselli M. A reevaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudunal study. Clin Cancer Res 2001; 7: 2357-62.
32. Tangkijvanich P, Anukulkarnkudol N, Suwongool P, Lertmnharit S, Hanvivatvong O, Kullavanijaya P, Poovorawo Y. Clinical characteristics and prognosis of hepatocellular carcinoma. J. Clin Gastroenterol 2000; 31: 302-8.
33. Safi F, Kohler I, Rottinger E, Beger HG. The value of the tumor marker CA15-3 in diagnosis and monitoring breast cancer. Cancer 1991; 68: 574-82.
34. Nihlinski J, Furman M, Clinical tumor markers in lung cancer. Eur J Cancer Prev 1995; 4: 129-30.
35. Grotowski M, Maruszynski M, PieChota W. Usefulness of preoperative assay CEA and CA19-9 in colo-rectal cancer patients. Pol Merkuriusz Lek 2001; 11: 476-9.
36. Panich V, Pornpatkul M, Sriroongrueng W. The problem of thalassemia in Thailand. Southeast Asian J. Trop Med Public Health 1992; 23(Suppl 2): 1-6.
37. Banfi G, Bravi S, Ardemagni A, Zerbi A. CA19-9, CA242 and CEA in the diagnosis and follow-up of pancreatic cancer. Int J Biol Markers 1996; 11: 77-81.